Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within 14 days of day 1
Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment).
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1 of FOLFIRI + bevacizumab initiation
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
Patients are excluded if they have had a biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to randomization
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 calendar days prior to the first dose of bevacizumab
Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within 14 days of day 1
Core biopsy or other minor surgical procedure (excluding placement of a vascular access device, paracentesis, and/or thoracentesis) within 7 days prior to the first date of bevacizumab therapy
Patients must not have experienced a core biopsy or other minor surgical procedure within 7 days prior to registration; NOTE: this excludes placement of a vascular access device up to 2 days prior to registration
Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within 14 days of day 1
Less than 7 days have passed from core biopsies or other minor surgical procedures excluding placement of a vascular access device
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
Care biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1; (minor surgical procedures include minimally invasive procedures such as fine needle aspiration, core biopsy, etc. requiring little if any supportive care excluding lumbar puncture and bone marrow aspiration/biopsy)
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device within 7 days prior to starting drug
(continued from no. 19) Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first date of bevacizumab therapy
Any surgical procedure, excluding central venous catheter placement, bone marrow biopsy, lumbar puncture, or other minor procedures (e.g., skin biopsy) within 14 days of day 1; patients who have undergone major surgery =< 21 days prior to starting study drug or who have not recovered from side effects of such procedure are ineligible for the study
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
Patients may not have had a core biopsy, skin cancer resection, or other minor surgical procedure, including placement of a vascular access device, within 7 days prior to Day 1 of the protocol.
Bleeding risks: Required to be on therapeutic anticoagulation (aspirin is allowed), coagulopathy (e.g. hemophilia or von Willebrand's disease); any grade III or greater hemorrhage, major surgical procedure, or significant trauma within 28 days; core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days
Core biopsy or other minor surgical procedure within 7 days prior to study start
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 3 days prior to the first dose of bevacizumab or vanucizumab
